PHARMAC is seeking feedback on a proposal to list ceftaroline fosamil in Part II of Section H of the Pharmaceutical Schedule, through a provisional agreement with AstraZeneca Limited.

In summary, this proposal is to list ceftaroline fosamil for use in DHB hospitals for multi-resistant organism salvage therapy from 1 November 2014.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2014-09-05-ceftaroline-fosamil/